Essential Partners’s INmune Bio INMB Stock Holding History

Essential Partners’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$170	Sell	87 -805	-90%	-$1.66K	﹤0.01%	2627
2026 Q2	$1.45K	Sell	892 -1,279	-59%	-$1.77K	﹤0.01%	2095
2026 Q1	$2.45K	Buy	2,171 +2,162	+24,022%	+$3.08K	﹤0.01%	1917
2025 Q4	$14	Buy	+9	New	+$16	﹤0.01%	2737

Other funds holding INMB

BFA

Bill Few Associates Pittsburgh, Pennsylvania $485M AUM 17.8% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Essential Partners's INMB Position: Q3 2026 in Review

Essential Partners reduced its INmune Bio (INMB) stake by 90% in Q3 2026, selling an estimated $1.66K and leaving 87 shares worth $170. The position accounts for ﹤0.01% of the portfolio, ranked #2627.

Essential Partners first reported a position in INMB in Q4 2025 and has held it in 4 quarters since. The position peaked at $2.45K in Q1 2026. 5 funds tracked by Wall St. Rank hold INMB as of Q3 2026.

Essential Partners held 87 shares of INmune Bio worth $170 as of Q3 2026.
Essential Partners sold 805 INmune Bio shares in Q3 2026, an estimated $1.66K.
INmune Bio made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2627 holding.
Essential Partners first reported a position in INmune Bio in Q4 2025 and has held it in 4 quarters since.
Essential Partners's INmune Bio position peaked at $2.45K in Q1 2026.
5 funds tracked by Wall St. Rank held INmune Bio as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.